News / Health

GSK Cancer Vaccine Fails Again, Testing Continues

FILE - The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai.
FILE - The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai.
Reuters
An experimental cancer vaccine from GlaxoSmithKline has failed in a second test - this time against lung cancer - but the British company said it still hoped to identify a sub-group of patients on which it would work.
 
Thursday's news that the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in a late-stage study is a further blow to the high-risk, high-reward project after a similar setback in melanoma in September.
 
Unlike traditional preventative vaccines, the MAGE-A3 treatment is designed for people with established disease, helping their immune systems to prevent the return of disease after surgery.
 
The large Phase III study, involving more than 2,000 lung cancer patients, found that the experimental therapy did not help patients live longer without their disease recurring.
 
Nonetheless, GSK plans to continue the clinical trial in the hope of finding a sub-population that will benefit. It is also doing the same with patients suffering from melanoma and results of analyzes looking at these sub-sets of patients with particular genetic profiles are expected in 2015.
 
Vincent Brichard, head of immunotherapeutics at GSK Vaccines, said the company was disappointed by the outcome but remained committed to the project.
 
Shares in GSK fell by 2 percent by 0945 GMT, underperforming a 0.7 percent decline in the European drugs sector.
 
Many investors had been expecting a disappointing read-out from the lung cancer study, following the earlier setback in melanoma, and there are doubts as to whether GSK will be able to prove the vaccine works for a smaller group of genetically selected patients.
 
But despite the problems GSK Chief Executive Andrew Witty painted a surprisingly upbeat picture of prospects for MAGE-A3 at full-year results last month. Witty described the cancer vaccine and another drug for heart disease called darapladib that has also disappointed in tests as among the most promising in the company's pipeline.
 
10 percent chance
 
Citi analyst Andrew Baum said he estimated there was a 10 percent probability that MAGE-A3 could result in a significant benefit in a gene-signature defined population group, which would still be a substantial market.
 
As a result, Citi has a risk-adjusted sales forecast for the product of 216 million pounds ($360 million) in 2022.
 
Other companies, including Bristol-Myers Squibb, Roche and Merck & Co, have had some recent notable successes in clinical trials of innovative drugs to boost the immune system, but GSK is still pushing the scientific boundaries with its vaccine-based approach.
 
So-called immunotherapy, in which the body's own immune system is enlisted to fight tumor cells, is a hot area of pharmaceutical research and development at the moment, although cancer vaccines have proved difficult to develop over the years.
 
U.S.-based Agenus has contributed technology to the GSK vaccine and its shares are sensitive to news on the project. The vaccine contains Agenus' QS-21 Stimulon adjuvant, or booster.
 
Although news on MAGE-A3 and darapladib has been disappointing for GSK, the company's overall drug research has been improving recently, with notable new drug approvals in 2013 for HIV, cancer and respiratory disease.
 
GSK, which is the only major drugmaker to report its internal rate of return on R&D investment, said last month that returns had now reached 13 percent, up from 12 percent two years earlier and 11 percent in 2010. It has set a target of reaching 14 percent.

You May Like

Koreas Mark 61st Anniversary of War Armistice

Muted observances on both sides of heavily-armed Demilitarized Zone that separates two decades-long enemies More

Judge Declares Washington DC Ban on Public Handguns Unconstitutional

Ruling overturns capital city's prohibition on carrying guns in pubic More

Pricey Hepatitis C Drug Draws Criticism

Activists are using the International AIDS Conference to criticize drug companies for charging high prices for life-saving therapies More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Students in Business for Themselvesi
X
Mike O'Sullivan
July 26, 2014 11:04 AM
They're only high school students, but they are making accessories for shoes, fabricating backpacks and doing product photography - all through their own businesses. It's the result of a partnership between a non-profit organization that teaches entrepreneurship and their schools. VOA's Mike O'Sullivan and Deyane Moses met the budding entrepreneurs near Los Angeles.
Video

Video Students in Business for Themselves

They're only high school students, but they are making accessories for shoes, fabricating backpacks and doing product photography - all through their own businesses. It's the result of a partnership between a non-profit organization that teaches entrepreneurship and their schools. VOA's Mike O'Sullivan and Deyane Moses met the budding entrepreneurs near Los Angeles.
Video

Video Astronauts Train in Underwater Lab

In the world’s only underwater laboratory, four U.S. astronauts train for a planned visit to an asteroid. The lab - called Aquarius- is located five kilometers off Key Largo, in southern Florida. Living in close quarters and making excursions only into the surrounding ocean, they try to simulate the daily routine of a crew that will someday travel to collect samples of a rock orbiting far away from earth. VOA’s George Putic has more.
Video

Video Not Even Monks Spared From Thailand’s Junta-Backed Morality Push

With Thailand’s military government firmly in control after May’s bloodless coup, authorities are carrying out plans they say are aimed at restoring discipline, morality and patriotism to all Thais. The measures include a crackdown on illegal gambling, education reforms to promote students’ moral development, and a new 24-hour phone hotline for citizens to report misbehaving monks. Steve Sandford reports from Bangkok.
Video

Video Virtual Program Teaches Farming Skills

In a fast-changing world beset by unpredictable climate conditions, farmers cannot afford to ignore new technology. Researchers in Australia are developing an online virtual world program to share information about climate change and more sustainable farming techniques for sugar cane growers. As VOA's Zlatica Hoke reports, the idea is to create a wider support network for farmers.
Video

Video Airline Expert: Missile will Show Signature on Debris

The debris field from Malaysia Airlines Flight 17 is spread over a 21-kilometer radius in eastern Ukraine. It is expected to take investigators months to sort through the airplane pieces to learn about the missile that brought down the jetliner and who fired it. VOAs Carolyn Presutti explains how this work will be done.
Video

Video Treatment for Childhood Epilepsy Heats up Medical Marijuana Debate

In the United States, marijuana is classed as an illegal drug by the federal government. But nearly half the states have legalized it, to some degree. Proponents say some strains of marijuana might have exceptional health benefits, for treating pain or inflammation in chronic conditions such as cancer, multiple sclerosis and epilepsy. Shelley Schlender reports on a strain of medical marijuana developed in Colorado that is reputed to reduce seizures in childhood epilepsy
Video

Video Airbus Adds Metal 3D Printed Parts to New Jets

By the end of this year, European aircraft manufacturing consortium Airbus plans to deliver the first of its new, extra-wide-body passenger jets, the A350-XWB. Among other technological innovations, the new plane will also incorporate metal parts made in a 3-D printer. VOA's George Putic has more.
Video

Video AIDS Conference Welcomes Exciting Developments in HIV Treatment, Prevention

Significant strides have been made in recent years toward the treatment and prevention of HIV, the virus that causes AIDS. This year, at the International AIDS Conference, the AIDS community welcomed progress on a new pill that may prevent transmission of the deadly virus. VOA’s Anita Powell reports from Melbourne, Australia.
Video

Video IAEA: Iran Turns its Enriched Uranium Into Less Harmful Form

Iran has converted its stockpiles of enriched uranium into a less dangerous form that is more difficult to use for nuclear weapons, according to the United Nations’ Atomic Energy Agency. The move complies with an interim deal reached with Western powers on Iran's nuclear program last year, in exchange for easing of sanctions. Henry Ridgwell reports for VOA from London.

AppleAndroid